Logo image
Distribution of 111in‐ and 125i‐labeled monoclonal antibody 17‐1a in mice bearing xenografts of human pancreatic carcinoma hup‐t4
Journal article   Open access   Peer reviewed

Distribution of 111in‐ and 125i‐labeled monoclonal antibody 17‐1a in mice bearing xenografts of human pancreatic carcinoma hup‐t4

Masatoshi Maeda, Miki Shoji, Toshiyuki Kawagoshi, Ryusuke Futatsuya, Takashi Honda and Luther W. Brady
Cancer, v 73(S3), pp 800-807
01 Feb 1994
PMID: 8306263
url
https://doi.org/10.1002/1097-0142(19940201)73:3+<800::aid-cncr2820731309>3.0.co;2-pView
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open
url
https://doi.org/10.1002/1097-0142(19940201)73:3+<800::AID-CNCR2820731309>3.0.CO;2-PView
Published, Version of Record (VoR) Open

Abstract

indium radioisotopes iodine radioisotopes monoclonal antibodies pancreatic neoplasms radioimmunodetection radioimmunotherapy
Background. The prognosis of pancreatic adenocarcinoma still remains poor because of the lack of reliable diagnostic tests for early stages of the disease. Monoclonal antibody 17‐1A(MoAb 17‐1A) has been studied extensively, and the antigen recognized by MoAb 17‐1A is expressed by adenocarcinomas of the pancreas and stomach, as well as other normal and malignant epithelial tissues. The potential of MoAb 17‐1A was investigated for its ability to detect pancreatic carcinomas. The use of MoAb 17‐1A in treatment also was studied. Methods. Immunoreactivity of MoAb 17‐1A with human pancreatic carcinoma cell line HuP‐T4 was examined histochemically by the avidin‐biotinylated enzyme complex method. MoAb 17‐1A was labeled with 125I by the Iodogen method and 111In using either diethylenetriaminepentaacetic anhydride (cDTPA) or 1‐(p‐benzyldiazonium) diethylenetriaminepentaacetic acid (aDTPA). After injection in nude mice bearing HuP‐T4 xenografts, the biodistribution of 111In‐ and 125I‐labeled MoAb 17‐1A was examined at various time points. Results. Positive staining of MoAb 17‐1A was noted for HuP‐T4 cells. A statistically significant (P < 0.01) greater tumor uptake was observed at 3 days after intravenous injection of 125I‐labeled MoAb 17‐1A when compared with 125I‐labeled nonspecific immunoglobulin G. 125I‐ and 111In‐labeled MoAb 17‐1A was concentrated in HuP‐T4 carcinoma 1.9–4.8 times higher than in the spleen, heart, liver, and pancreas. Conclusions. MoAb 17‐1A was found to bind selectively to human pancreatic carcinoma HuP‐T4. Tumor exhibited higher uptake of radiolabeled MoAb 17‐1A compared with adjacent normal tissues. These results suggest that MoAb 17‐1A may be applicable to the radioimmunodetection and radioimmunotherapy of pancreatic adenocarcinomas. Cancer 1994; 73:800–7.

Metrics

14 Record Views
14 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Logo image